PATENT CLAIM ANALYSIS

Application Number: 16180316
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-03
Patent Classification: ["514", "469000"]

Abstract:
Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

Claim (Index 18):
A method for the chronic treatment of Non-24 in a person who is totally blind comprising orally administering to the person tasimelteon in an amount of 20 to 50 mg once daily about \u00bd hour to about 1\u00bd hours before the desired bedtime.

Metadata:
- Claim Count in Document: 36.0
- Percentile: 98.0
- Lexical Diversity: 1.44828
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14374257', '13751011', '15378353', '15382526', '15822162']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8075474156473861
- 35 USC 102 Novelty (BERT): 0.6060499558073288
- Combined Prediction Score: 0.7873976696633803
- Mean Citation Score: 602.356314
- Max Citation Score: 616.0619
- Similarity Product: 464.14813954598907

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test